Metformina + Vildagliptina Teva (Metformin Hydrochloride, Vildagliptin)

Metformin reduces hepatic glucose production and increases peripheral insulin sensitivity. Vildagliptin blocks the DPP‑4 enzyme, raising levels of incretin hormones that stimulate insulin release and suppress glucagon. The dual action addresses both insulin resistance and impaired insulin secretion, providing complementary glucose‑lowering effects.

The exact dose is determined by the prescribing clinician based on the patient’s renal function, glycemic targets, and tolerability. The prescriber will select the appropriate strength and titration schedule, and patients should follow the individualized dosing instructions provided.

Safety data in pregnancy are limited, and the product should only be used if the potential benefit outweighs any possible risk to the fetus. Breastfeeding mothers should consult their healthcare provider, as metformin is excreted in milk and the effects of vildagliptin are not fully known.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with sulfonylureas, the metformin‑vildagliptin combo offers a lower risk of hypoglycemia and weight gain. Relative to other DPP‑4 inhibitors, vildagliptin provides similar efficacy but may differ in dosing frequency. The addition of metformin adds insulin‑sensitising benefits not present with DPP‑4 inhibitor monotherapy.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

The medication is taken orally, usually with meals to reduce gastrointestinal discomfort. Tablets should be swallowed whole with a full glass of water. Patients should not crush or chew the tablets unless specifically instructed by a healthcare professional.

The most critical adverse events include metformin‑related lactic acidosis, severe hypoglycemia (especially when combined with other glucose‑lowering agents), acute pancreatitis, and rare but serious skin reactions such as Stevens‑Johnson syndrome. Prompt medical attention is required if any of these occur.

The combination is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin or vildagliptin, and those with acute or chronic metabolic acidosis. Caution is also advised for individuals with significant hepatic disease.